Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene

Oncogene

Volumn 33, Issue 18, 2014, Pages 2405-2412

  Martin, D ^a   Nguyen, Q ^a   Molinolo, A ^a   Gutkind, J S ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

4EBP; Cancer; Kaposi's sarcoma; MTOR; PI3K; Rapamycin

Indexed keywords

ANGIOGENIC FACTOR; G PROTEIN COUPLED RECEPTOR; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4E BINDING PROTEIN 2; INITIATION FACTOR 4E BINDING PROTEIN 3; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN HERPESVIRUS 8; MOUSE; NONHUMAN; ONCOGENE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RNA TRANSLATION; SIGNAL TRANSDUCTION;

EUKARYOTA; HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; CARRIER PROTEINS; CELL TRANSFORMATION, VIRAL; EUKARYOTIC INITIATION FACTORS; HERPESVIRUS 8, HUMAN; HUMANS; ONCOGENES; PARACRINE COMMUNICATION; PHOSPHOPROTEINS; RECEPTORS, CHEMOKINE; SARCOMA, KAPOSI; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84899982907     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.193     Document Type: Article

References (28)

1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619.
3. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007; 13: 252-259.
4. Yanagiya A, Suyama E, Adachi H, Svitkin YV, Aza-Blanc P, Imataka H et al. Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol Cell 2012; 46: 847-858.
5. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
6. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7: 209-219.
7. Stallone G, Infante B, Grandaliano G, Schena FP, Gesualdo L. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int 2008; 21: 825-832.
8. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
9. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003; 3: 23-36.
10. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
11. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006; 1: 273-296.
12. Hosseini-Moghaddam SM, Soleimanirahbar A, Mazzulli T, Rotstein C, Husain S. Post renal transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy. Transpl Infect Dis 2012; 14: 338-345.
13. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10: 707-719.
14. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-592.
15. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10: 133-143.
16. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10: 395-403.
17. Martin D, Galisteo R, Ji Y, Montaner S, Gutkind JS. An NF-kappaB gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia. Oncogene 2008; 27: 1844-1852.
18. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 2004; 101: 4821-4826.
19. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868-880.
20. Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW et al. Development of ATP-competitive mTOR inhibitors. Methods Mol Biol 2012; 821: 447-460.
21. Gasperini P, Tosato G. Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma. Leukemia 2009; 23: 1867-1874.
22. Vuiblet V, Birembaut P, Francois A, Cordonnier C, Noel LH, Goujon JM et al. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrlo Dial Transplant 2012; 27: 411-416.
23. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res 2012; 72: 6468-6476.
24. Gasperini P, Sakakibara S, Tosato G. Contribution of viral and cellular cytokines to Kaposi's sarcoma-associated herpesvirus pathogenesis. J Leukoc Biol 2008; 84: 994-1000.
25. Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM et al. In vivorestricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 2007; 11: 245-258.
26. Cesarman E, Mesri EA, Gershengorn MC. Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J Exp Med 2000; 191: 417-422.
27. Vitale-Cross L, Molinolo AA, Martin D, Younis RH, Maruyama T, Patel V et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res 2012; 5: 562-573.
28. Bieleski L, Talbot SJ. Kaposi's sarcoma-associated herpesvirus vCyclin open reading frame contains an internal ribosome entry site. J Virol 2001; 75: 1864-1869.